Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

SNPX

Synaptogenix Inc

May 21 • 04:00PM ET

4.95

Dollar change +0.11
Percentage change 2.27	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-37.21	Insider Own	2.43%	Shs Outstand	1.23M	Perf Week	3.99%
Market Cap	6.09M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.20M	Perf Month	13.53%
Income	-12.23M	PEG	-	EPS next Q	-	Inst Own	3.97%	Short Float	2.51%	Perf Quarter	-25.42%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-62.35%	Short Ratio	0.54	Perf Half Y	-23.82%
Book/sh	20.32	P/B	0.24	EPS next Y	-	ROA	-13.75%	Short Interest	0.03M	Perf Year	-77.03%
Cash/sh	22.98	P/C	0.22	EPS next 5Y	-	ROE	-16.94%	52W Range	3.53 - 47.00	Perf YTD	-27.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.59%	ROI	-55.44%	52W High	-89.47%	Beta	1.50
Dividend TTM	-	Quick Ratio	4.58	Sales past 5Y	0.00%	Gross Margin	-	52W Low	40.33%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	4.58	EPS Y/Y TTM	-145.64%	Oper. Margin	0.00%	RSI (14)	55.62	Volatility	6.65% 8.18%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	350.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	93.78%	Payout	-	Rel Volume	0.11	Prev Close	4.84
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	-	Avg Volume	55.52K	Price	4.95
SMA20	5.59%	SMA50	5.23%	SMA200	-29.83%	Trades		Volume	6,144	Change	2.27%

May-20-24 11:54AM	SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 (InvestorPlace)
May-07-24 09:00AM	Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery (PR Newswire)
Apr-24-24 09:15AM	Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire)
Apr-09-24 09:15AM	Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics (PR Newswire) -8.35%
Apr-03-24 08:00AM	Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing (PR Newswire)
09:00AM	Loading…
Dec-19-23 09:00AM	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders (PR Newswire) +5.45%
Dec-06-23 09:00AM	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's (PR Newswire)
Nov-02-23 09:00AM	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology (PR Newswire)
Sep-26-23 09:00AM	Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease (PR Newswire) +5.67%
Sep-07-23 09:00AM	Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study (PR Newswire) -12.23%
Jul-19-23 09:00AM	Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis (PR Newswire)
Jul-13-23 09:00AM	Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience (PR Newswire) +20.79%
Mar-07-23 09:00AM	Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities (PR Newswire)
Dec-16-22 09:00AM	Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease (PR Newswire) -74.63%
Nov-18-22 09:00AM	Synaptogenix Announces $15 Million Private Placement with Existing Investors (PR Newswire) +12.72%
09:00AM	Loading…
Oct-19-22 09:00AM	Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 (PR Newswire)
Sep-28-22 11:50AM	Synaptogenix Welcomes Lecanemab Phase 3 Trial Results (PR Newswire)
Aug-12-22 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire) +5.10%
Jul-26-22 09:15AM	Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data (PR Newswire) +6.37%
Jul-21-22 09:15AM	Synaptogenix Announces Corporate Update Conference Call (PR Newswire)
Jul-20-22 09:15AM	Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data (PR Newswire) +5.81%
May-17-22 09:15AM	Synaptogenix to Present at the Cell Symposium (PR Newswire) +10.97%
Apr-19-22 09:15AM	Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial (PR Newswire) -5.69%
Apr-05-22 09:15AM	New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease (PR Newswire)
Mar-29-22 09:15AM	Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit (PR Newswire)
Mar-22-22 09:15AM	Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum (PR Newswire)
Mar-15-22 09:15AM	Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) (PR Newswire)
Feb-23-22 09:15AM	Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis (PR Newswire)
Feb-07-22 09:38AM	Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ... (GuruFocus.com) -5.88%
Feb-01-22 09:15AM	Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients (PR Newswire) +29.36%
11:58AM	Loading…
Dec-06-21 11:58AM	We're Hopeful That Synaptogenix (NASDAQ:SNPX) Will Use Its Cash Wisely (Simply Wall St.)
Sep-28-21 09:00AM	Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-10-21 09:00AM	Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-05-21 10:00AM	Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome (PR Newswire) -6.18%
Jul-26-21 09:15AM	Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021 (PR Newswire) -19.09%
Jul-21-21 09:00AM	Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings (PR Newswire) +19.86%
Jul-14-21 09:00AM	Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline (PR Newswire) +9.74%
Jul-07-21 09:00AM	Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease (PR Newswire) -13.16%
Jun-24-21 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire)
Jun-14-21 09:00AM	Synaptogenix Announces $12.5 Million Private Placement (PR Newswire)
Jun-09-21 09:00AM	Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update (PR Newswire)
05:38AM	Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-19-21 09:00AM	Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market (PR Newswire)
May-10-21 09:00AM	Synaptogenix, Inc: Invitation to the Benzinga Global Small Cap Conference (Newsfile) -12.50%
Apr-26-21 09:00AM	Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum (PR Newswire) +7.60%
Apr-01-21 09:00AM	Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update (PR Newswire)
Mar-05-21 09:00AM	Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference (PR Newswire) -8.16%
Feb-25-21 09:12AM	Synaptogenix to Present at Upcoming Scientific Industry Conferences (PR Newswire)
Feb-12-21 09:00AM	Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference (PR Newswire)
Feb-09-21 09:00AM	Synaptogenix Files Application to List on the Nasdaq Stock Market (PR Newswire) +20.83%

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNPX

Synaptogenix Inc

Upgrade your FINVIZ experience